Improving Management of Viral Febrile Illness and Reducing the Need for Empiric Antibiotics Using VIDAS® Immunoassay for Dengue and Chikungunya: A West African Multicentric Study
Authors:
- Fanette RavelFRFanette Ravel
- Solenne RobertSRSolenne Robert
- Diakourga Arthur DjibougouDDDiakourga Arthur Djibougou
- Kigninlman HoroKHKigninlman Horo
- Aristophane TanonATAristophane Tanon
- Privat AngoPAPrivat Ango
- Palpouguini Félix LompoPLPalpouguini Félix Lompo
- Faustine MeynierFMFaustine Meynier
- Ludovic BrossaultLBLudovic Brossault
- Umit GulerUGUmit Guler
- Jacques SimporeJSJacques Simpore
- Potiandi Serge DiagbougaPDPotiandi Serge Diagbouga
Open Access
- 8 September 2025
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 15 (17) , 2269
Abstract
Background: Dengue and chikungunya are endemic in West Africa, posing significant public health issues. The aim of this study was to evaluate the impact of differential and systematic diagnosis of dengue and chikungunya on patient management and on antibiotic use in Burkina Faso and Ivory Coast. Methods: A multicenter prospective cohort study was conducted in both countries involving patients with suspected dengue and/or chikungunya viremia. VIDAS® diagnostic tests (bioMérieux SA, Marcy-l’Étoile, France) were provided to the intervention sites, while the control sites initially followed standard of care before testing at the end of the study. The primary outcome was defined as antibiotic prescription or non-initiation/discontinuation, and the secondary endpoints included hospital resource use, patient satisfaction, and health-related quality of life (HRQoL), analyzed through Chi-square and logistic regression using SAS software v9.4. Results: Out of 775 enrolled patients, 767 had corresponding VIDAS® Dengue and VIDAS® Chikungunya results, with 570 having recorded antibiotic therapy (initiated, non-initiated or discontinued). Both Burkina Faso and Ivory Coast observed an increase in antibiotic discontinuation (or non-initiation) rates at the intervention sites compared to control sites: increased from 60% to 78% in Burkina Faso and from 36% to 83% in Ivory Coast. Hospitalization rates within seven days following inclusion were also lower in intervention sites than in the control sites: Burkina Faso 41% as compared with 97% and Ivory Coast 24% as compared with 98%. Patient-reported antibiotic use within seven days post-inclusion was also significantly lower in intervention sites. Conclusions: The results showed a reduction in potential antibiotic overuse and hospital admissions (i.e., hospitalization rates within seven days) in both the Burkina Faso and Ivory Coast interventions sites. These findings emphasize the importance of enhanced diagnostic strategies for the improvement of patient outcomes and the fight against antibiotic resistance. This study also highlights the need for implementing systematic and differential diagnosis of dengue and chikungunya in West Africa where febrile infections are endemic. Further studies are warranted to explore the economic benefits of these diagnostic strategies.Keywords
Funding Information
- bioMérieux
This publication has 30 references indexed in Scilit:
- Current Status of Malaria Control and Elimination in Africa: Epidemiology, Diagnosis, Treatment, Progress and ChallengesJournal of Epidemiology and Global Health, 2024
- Dengue vector habitats in Ouagadougou, Burkina Faso, 2020: an unintended consequence of the installation of public handwashing stations for COVID-19 preventionThe Lancet Global Health, 2024
- Severe dengue in adults and children, Ouagadougou (Burkina Faso), West Africa, October 2015–January 2017IJID Regions, 2021
- ChikungunyaInfectious Disease Clinics of North America, 2019
- Simultaneous detection of Dengue virus, Chikungunya virus, Zika virus, Yellow fever virus and West Nile virusJournal of Virological Methods, 2019
- A scoping review of Chikungunya virus infection: epidemiology, clinical characteristics, viral co-circulation complications, and controlActa Tropica, 2018
- Chikungunya VirusClinics In Laboratory Medicine, 2017
- Expression, refolding and bio-structural analysis of a tetravalent recombinant dengue envelope domain III protein for serological diagnosisProtein Expression and Purification, 2017
- Dengue: knowledge gaps, unmet needs, and research prioritiesThe Lancet Infectious Diseases, 2017
- Chikungunya in the AmericasThe Lancet, 2014